Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Opens Its Wallet For Early Immunology Tie-Up With ImmuNext

Executive Summary

Lilly is prepared to splash over $600m on an early development deal with ImmuNext on an immunometabolism target which ties the companies together for three years while an antibody is being developed.

You may also be interested in...



Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration

Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.

GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket

GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel